According to the committee, the medical groups "served as components of a coordinated public relations strategy by Sanofi to ... prevent or delay generic alternatives to its blockbuster drug."
Documents obtained by investigators show that Sanofi donated more than $2 million each to the Society of Hospital Medicine and the North American Thrombosis Forum. The groups did not disclose the payments in their letters to FDA last year. The letters to the FDA were first reported by The Wall Street Journal.
Paris-based Sanofi said in a statement the medical groups "brought legitimate and important patient safety facts and considerations to the attention of the FDA."
No hay comentarios:
Publicar un comentario